Related Experiment Video

Updated: Mar 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Statin therapy and inflammation in patients with diabetes treated with high dose aspirin

Rahul Chaudhary1, Kevin P Bliden2, Jalaj Garg3

  • 1Johns Hopkins University/Sinai Hospital of Baltimore, Baltimore, MD, USA.

Journal of Diabetes and Its Complications
|May 31, 2016
PubMed

Insights

Statin and aspirin therapy in diabetic patients with coronary artery disease (CAD) reduces blood thrombogenicity and inflammation. Urinary 11-dehydrothromboxane B2 (11-dh-TxB2) may help personalize statin treatment for better outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomarkers

Background:

  • Statin and aspirin are standard treatments for coronary artery disease (CAD) in diabetic patients.
  • The impact of statins on blood thrombogenicity and inflammation in this population is not well understood.

Purpose of the Study:

  • To investigate the effects of statin therapy on blood thrombogenicity and inflammation markers in diabetic patients with suspected CAD.
  • To explore the relationship between statin use and specific biomarkers like urinary 11-dehydrothromboxane B2 (11-dh-TxB2).

Main Methods:

  • 209 diabetic patients with suspected CAD undergoing cardiac catheterization were grouped by statin use.
  • Measurements included urinary 11-dh-TxB2, lipid profiles, oxidized-LDL/β2GPI, and thrombogenicity assays (thrombelastography, aggregometry).
  • Coronary artery disease severity was classified based on diameter stenosis.

Main Results:

  • Patients on statins showed significantly lower levels of 11-dh-TxB2, collagen-induced aggregation, total cholesterol, LDL, oxidized-LDL, Apo B100, and ApoB100/A1 ratio.
  • A lower proportion of statin users had high urinary 11-dh-TxB2 levels compared to non-users (25% vs. 57%, p=0.01).
  • CAD severity was distributed as 66% severe, 19% moderate, and 15% no/minor CAD.

Conclusions:

  • Statin therapy, in addition to aspirin, provides significant anti-inflammatory and antithrombotic benefits in diabetic patients with CAD.
  • Urinary 11-dh-TxB2 emerges as a potential biomarker for tailoring statin therapy in this patient group.
Abstract

Keywords:
11-Dehydrothromboxane B2CADDiabetesInflammationStatin

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
569
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
407
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
979
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
391
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
559